Baxter International Inc. announced that it has agreed to acquire German biopharmaceutical company SuppreMol, expanding its portfolio of drugs for autoimmune diseases. Baxter is paying $225 million before working capital and other adjustments for the privately-held company, gaining SuppreMol’s early-stage development portfolio of novel biologic immunoregulatory therapeutics for treatment of …